Two Studies Evaluating the Combination of REVLIMID ® and rituximab in Non ... EON: Enhanced Online News (press release) “The increasing volume of clinical evidence evaluating combinations utilizing REVLIMID plus rituximab provide us powerful insight into the potential of antibody-dependent cellular cytotoxicity in lymphomas, and the potential of these novel combinations ... |
